https://exciva.com/hello-world/2026-08-14T08:40:24+00:00https://exciva.com/news-article-2/2026-05-29T17:18:05+00:00https://exciva.com/exciva-gmbh-today-announces-the-closing-of-a-e51-million-59m-series-b-financing-round/2026-08-10T15:19:17+00:00https://exciva.com/fiona-hattey-joined-the-exciva-team-as-head-of-clinical-operations-she-has-over-thirty-years-of-experience-in-operationalizing-clinical-trials/2026-08-11T08:59:26+00:00https://exciva.com/our-lead-program-exv-802-for-the-treatment-of-agitation-in-dementia-associated-with-alzheimers-disease-received-a-fast-track-designation-from-the-us-fda/2026-08-14T08:55:20+00:00https://exciva.com/dr-hans-moebius-co-founder-of-exciva-re-joined-the-team-as-a-chief-medical-officer-bringing-with-him-over-thirty-years-of-leadership-in-neurology-and-psychiatry-drug-development-and-translational-me/2026-08-14T08:55:12+00:00https://exciva.com/francisco-orellana-a-seasoned-professional-who-has-worked-in-the-biotech-sector-for-over-twenty-years-joined-exciva-as-chief-financial-officer/2026-08-14T08:55:06+00:00https://exciva.com/the-us-pto-granted-a-patent-to-exciva-for-its-invention-of-innovative-composition-of-matter-with-various-therapeutic-uses-in-neuropsychiatry/2026-08-14T08:54:58+00:00https://exciva.com/exciva-successfully-completed-phase-i-study-of-its-proprietary-exv-802-combination-of-dextromethorphan-and-a-5-ht2a-2c-receptor-inverse-agonist/2026-08-14T08:54:51+00:00https://exciva.com/exciva-raises-e9-million-in-series-a-round-led-by-andera-partners/2026-08-14T08:57:29+00:00